Skip to main content

Aurinia Pharmaceuticals Inc.

corporate_fare Company Profile

Aurinia Pharmaceuticals Inc.

AUPH·NASDAQ·Life Sciences·CIK 0001600620

Aurinia is a biopharmaceutical company focused on delivering therapies for people with autoimmune diseases. In January 2021, the company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for treating adult patients with active lupus nephritis ("LN"). Aurinia is also developing aritinercept, which is a dual inhibitor of B cell-activating factor ("BAFF") and a proliferation-inducing ligand ("APRIL"), for potential treatment of autoimmune diseases. Aurinia sells LUPKYNIS to two specialty pharmacies and a specialty distributor in the United States. The company also sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. ("Otsuka"), for the European and Japanese markets. For the year ended December 31, 2025, net product sales were $271.3 million, a 25% increase compared to $216.2 million in 2024. Cash flows from operating activities for the year ended December 31, 2025, were $135.7 million, up 206% compared to $44.4 million in 2024. As of December 31, 2025, Aurinia had cash, cash equivalents, restricted cash, and investments of $398.0 million, compared to $358.5 million at December 31, 2024. For the year ended December 31, 2025, the company repurchased 12.2 million of its common shares for $98.2 million. In December 2020, Aurinia entered into a collaboration and licensing agreement with Otsuka to develop and commercialize oral voclosporin in Japan, the European Union, the United Kingdom, Switzerland, Russia, Norway, Belarus, Iceland, Liechtenstein, and Ukraine. This agreement included a $50 million upfront cash payment, regulatory and commercial milestone payments, and royalties ranging from 10% to 20% on net sales in these territories. In August 2022, Aurinia also entered into a commercial supply agreement with Otsuka to supply LUPKYNIS inventory at cost plus a margin, and to provide manufacturing and other services, including sharing the capacity of a dedicated manufacturing facility at Lonza Ltd., Aurinia's contract manufacturing partner for voclosporin.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for AUPH at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-30, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for AUPH spans 10-Q, 8-K, SCHEDULE 13D/A, 4.

Recent high-impact activity:

  • Aurinia 10-Q Details Q3: $83.7M Revenue, $31.7M Net Income, $486.9M Cash
  • Aurinia Lifts 2026 Revenue Guidance After Q3 Sales Rise 14%
  • Aurinia Settles Teva Patent Litigation, Secures LUPKYNIS Exclusivity Until December 2036
  • Aurinia Settles Patent Fight With Teva Over Generic Voclosporin
  • Aurinia Q2 2026: LUPKYNIS Sales Surge 19% to $79.4M, Net Income Hits $37.4M

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$283.06M
Net Income
$287.2M
Diluted EPS
$2.07
Op. Cash Flow
$135.66M
Gross Profit
$250.39M
Operating Income
$104.91M
Cash & Equivalents
$80.16M
Debt / Equity
0.00×
Net Margin
101.5%
Shares Outstanding
132.32M sh
Source: 10-K · filed 2026-02-26 · accession 0001600620-26-000017

Short Interest & Short Volume

10.31 days to cover

FINRA reported short interest of 7,137,632 shares in AUPH as of the October 30, 2026 settlement, a 8.3% decrease from the prior period — about 10.3 days to cover at its recent average daily volume. On November 20, 2026, 31.4% of AUPH volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)7,137,632 shares as of October 30, 2026
Change vs prior period▼ 8.3%
Days to cover10.31 at avg daily volume of 692,192
Daily short volume (FINRA facilities)31.4% of 463,534 shares on November 20, 2026
5-day average short volume36.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$14.64 -0.41% today
52-week range · as of 2026-10-30 $11.96 – $19.25
Market cap
$1.97B
Volume
1.3M (1.5× avg)
3-mo avg 923K
Live data · 2026-11-22 07:37 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AUPH - Latest Insights

AUPH
Oct 30, 2026, 8:07 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $16.62
Real-time Price: $14.64 info
Change: -$1.98 (-12%) info
Market Cap: $1.97B info
AUPH
Oct 30, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $17.21
Real-time Price: $14.64 info
Change: -$2.57 (-15%) info
Market Cap: $1.97B info
AUPH
Aug 19, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.34
Real-time Price: $14.64 info
Change: -$1.70 (-10%) info
Market Cap: $1.97B info
AUPH
Aug 19, 2026, 4:07 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $16.57
Real-time Price: $14.64 info
Change: -$1.93 (-12%) info
Market Cap: $1.97B info
AUPH
Aug 06, 2026, 8:16 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $15.75
Real-time Price: $14.64 info
Change: -$1.11 (-7%) info
Market Cap: $1.97B info
AUPH
Aug 06, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.85
Real-time Price: $14.64 info
Change: -$1.21 (-8%) info
Market Cap: $1.97B info
AUPH
Aug 06, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $15.75
Real-time Price: $14.64 info
Change: -$1.11 (-7%) info
Market Cap: $1.97B info
AUPH
Jun 04, 2026, 6:44 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $16.36
Real-time Price: $14.64 info
Change: -$1.72 (-11%) info
Market Cap: $1.97B info
AUPH
Jun 04, 2026, 7:07 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $15.82
Real-time Price: $14.64 info
Change: -$1.18 (-7%) info
Market Cap: $1.97B info
AUPH
Jun 02, 2026, 9:54 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $15.39
Real-time Price: $14.64 info
Change: -$0.7509 (-5%) info
Market Cap: $1.97B info
AUPH
Jun 02, 2026, 4:13 PM EDT
Filing Type: 144
Importance Score:
9
Price at Filing: $15.39
Real-time Price: $14.64 info
Change: -$0.7509 (-5%) info
Market Cap: $1.97B info
AUPH
May 11, 2026, 4:11 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $15.72
Real-time Price: $14.64 info
Change: -$1.08 (-7%) info
Market Cap: $1.97B info
AUPH
May 11, 2026, 4:10 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $15.72
Real-time Price: $14.64 info
Change: -$1.08 (-7%) info
Market Cap: $1.97B info
AUPH
May 11, 2026, 9:20 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $15.49
Real-time Price: $14.64 info
Change: -$0.8509 (-5%) info
Market Cap: $1.97B info
AUPH
May 07, 2026, 8:23 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $16.30
Real-time Price: $14.64 info
Change: -$1.66 (-10%) info
Market Cap: $1.97B info
AUPH
May 07, 2026, 8:22 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.30
Real-time Price: $14.64 info
Change: -$1.66 (-10%) info
Market Cap: $1.97B info
AUPH
May 07, 2026, 8:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $16.30
Real-time Price: $14.64 info
Change: -$1.66 (-10%) info
Market Cap: $1.97B info
AUPH
Apr 21, 2026, 4:31 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $15.82
Real-time Price: $14.64 info
Change: -$1.18 (-7%) info
Market Cap: $1.97B info
AUPH
Apr 03, 2026, 4:56 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.63
Real-time Price: $14.64 info
Change: -$0.991 (-6%) info
Market Cap: $1.97B info
AUPH
Mar 30, 2026, 9:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $14.33
Real-time Price: $14.64 info
Change: +$0.3091 (+2%) info
Market Cap: $1.97B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets